Linked Life Data

16774579

Source:http://linkedlifedata.com/resource/pubmed/id/16774579

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-6-15
pubmed:abstractText
Immune-mediated dermatoses, such as psoriasis and atopic dermatitis, affect a significant proportion of the population. Although most cases are not life threatening, these diseases can have a profound effect on the sufferer's quality of life and that of their family. Systemic therapy, such as ciclosporin, is often indicated for severe or recalcitrant disease. The efficacy of ciclosporin in the treatment of psoriasis and atopic dermatitis has been established and clinical data also demonstrate its efficacy in treating less common but equally challenging conditions such as pyoderma gangrenosum, lichen planus, autoimmune bullous disease, recalcitrant chronic idiopathic urticaria and chronic dermatitis of the hands and feet. The risk of potential adverse events associated with ciclosporin is greatly reduced if current treatment and monitoring guidelines are followed.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0007-0963
pubmed:author
pubmed:issnType
Print
pubmed:volume
155 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-16
pubmed:dateRevised
2007-11-13
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Update on the use of ciclosporin in immune-mediated dermatoses.
pubmed:affiliation
Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK. christopher.griffiths@manchester.ac.uk
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't